西酞普兰与阿普唑仑治疗广泛性焦虑症对照研究

目的探讨西酞普兰治疗广泛性焦虑症的临床疗效及安全性。方法将66例广泛性焦虑症患者随机分为研究组34例，对照组32例，研究组口服西酞普兰治疗，对照组口服阿普唑仑治疗，观察6w。于治疗前及治疗第1w、2w、4w、6w末采用汉密顿焦虑量表与焦虑自评量表评定临床疗效，副反应量表评定不良反应。结果治疗6w末，研究组显效率61．76％，有效率85．29％；对照组分别为56．25％，81.25％。汉密顿焦虑量表与焦虑自评量表评分，两组治疗1w末起均较治疗前有显著下降（P〈0．05或0．01），并随治疗时间的延续均呈持续性下降；同期两组间比较均无显著性差异（P〉0．05）。副反应量表评分研究组自主神经因子分显著低于对照组（t=2．474，P〈0．05）。结论西酞普兰治疗广泛性焦虑疗效肯定，安全性高，依从性好。

A control study of citalopram vs. alprazolam in generalized anxiety disorder

Objective To explore the efficacy and safety of citalopram in generalized anxiety disorder（GAD）. Methods 66 GAD patients were randomly divided into research group（n= 34） which took orally citalopram and control group（n=32） which did alprazolam for 6 weeks. Curative effects were assessed with the Hamilton Anxiety Scale（HAMA） and the Self-rating Anxiety Scale（SAS） and adverse reactions with the Treatment Emergent Symptom Scale（TESS） before treatment and at the ends of the 1^st ,2^nd 4^th and 6^th week treatment. Results At the end of the 6^th week,excellence and effectiveness rates were 61. 76% and 85.29% in the research group and 56.25 % and 81.25 % in the control group,respectively. HAMA and SAS scores of both groups lowered more significantly since the end of the 1^st week compared with pretreatment （P〈0.05 or 0. 01） and did continously along with therapy lasting. There was no significant difference in synchronization intergroup comparison （P〉0.05）. The autonomic nerves score of the TESS was significantly lower in the research than in the control group（P〈0.05）. Conclusion Citalopram has positive efficacy,higher safety and better compliance in the treatment of generalized anxiety disorder.